According to the instruction for Nomination Committee in Ascelia Pharma AB (publ) adopted at the annual general meeting held on 23 November 2018, the Nomination Committee shall consist of four members, representing the three largest shareholders per the end of March, together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of March.
Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 14 November 2019 has been established to consist of the following persons together representing approximately 40 per cent of the shares and votes in the company:
- Jørgen Thorball, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
- Nils Lorentzen, appointed by CMC SPV of 3 April 2017 AB;
- Håkan Nelson, appointed by Øresund Healthcare Capital K/S; and
- Peter Benson, chairman of the board of directors.
The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2019 and on the company’s website, www.ascelia.com.
The duties of the Nomination Committee is to prepare and propose the following to the coming annual shareholders’ meeting: election of chairman at the shareholders’ meeting; election of chairman of the board of directors and other members of the board of directors; fees to the board of directors, divided between the chairman and other members, and any fees for committee work; election of auditor and fees to the auditor; and principles for appointment of the Nomination Committee.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail kb@ascelia.com. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 26 September 2019, to ensure that the proposals can be considered by the Nomination Committee.
The Nomination Committee’s proposals will be presented in the notice convening the AGM and on the company’s website.
For further information, please contact:
Magnus Corfitzen, CEO
Email: moc@ascelia.com
+46 735 179 110
Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60
The information was submitted for publication, through the agency of the contact person set out above, at 10.30 a.m. CET on 10 May 2019.
About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.
Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com